MonoSol seeks partners after reacquiring Zuplenz for cancer; microneedles best for H1N1 vaccine delivery;

> MonoSol Rx, which specializes in developing thin-film versions of existing drugs, has reacquired the commercial rights to Zuplenz from Strativa Pharmaceuticals and seeking partners to market the oral soluble film prescribed for the treatment of emetogenic cancer chemotherapy and radiotherapy-induced nausea and vomiting. MonoSol release

> A vaccine delivered to the skin using a microneedle patch gives better protection against the H1N1 influenza virus than a vaccine delivered through subcutaneous or intramuscular injection, say researchers from Emory University and Georgia Tech. Release

> University of South Florida researchers have used rat Sertoli cells to successfully deliver therapeutics deep into the lung. Sertoli cells are present in the testes and are also called "nurse" or "mother" cells because they nurture developing sperm cells. Release

> Medtronic warns of battery issue with drug-delivery pump. Item

> India's Venus Remedies has launched its Achnil pain-killer, an injection formulation that will "fill in the gap of long-standing demand for better pain management therapies, especially for the aged population," according to the company. Story

> Drug delivery patent application of the week: Drug Delivery Using Fine Fiber Encapsulation Application

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.